Even as other drugmakers are making big plays for business in Japan, India’s Lupin is backing off. Just weeks after selling the sterile manufacturing assets of its Kyowa to a private equity investor. More: Lupin sells off Japanese operation to
read moreThe results are from the largest placebo-controlled study ever undertaken in type I or III SMA patients. More: Roche’s risdiplam hits targets in SMA trial Source: News
read moreThe agreement is expected to be completed within 30-45 days. More: Horizon divests animal models business to Envigo Source: News
read moreTopline results showed that the drug didn’t meet the primary endpoints of superior overall survival, compared with standard of care. More: Bavencio falls at late-stage hurdle Source: News
read moreDespite the good news, there is still “disappointment surrounding the restrictions on prescribing cannabis-based drugs in the UK.” More: NICE U-turn for Epidyolex in epilepsy Source: News
read moreThe data marks an important milestone for CKD-related anaemia patients, as it is the “first innovation of its kind for this market in many years.” More: Roxadustat hits efficacy, CV targets in CKD-related anaemia Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals